Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Biogen Pharmachem Industries, at its meeting on 7 November 2025, approved the unaudited financial results for the quarter and half year ended 30 September 2025. The company reported zero revenue from operations for both Q2 and Q1 FY26, with all earnings coming from 'Other Income'. H1 FY26 net profit stood at Rs 85.33 lakhs (EPS Rs 0.01), but Q2 FY26 alone swung to a net loss of Rs 49.15 lakhs (vs Q1 FY26 profit of Rs 134.48 lakhs), as other income turned negative at Rs -10.49 lakhs in Q2. Total assets grew to Rs 9,917.53 lakhs (from Rs 9,201.77 lakhs at March 2025), with equity share capital rising to Rs 9,026.03 lakhs following the conversion of preferential warrants that brought in Rs 630 lakhs. Other equity, however, dropped sharply from Rs 2,666.74 lakhs to Rs 882.07 lakhs. The statutory auditors (Rishi Sekhri and Associates) issued an unqualified review report.
The complete absence of operating revenue makes the company heavily dependent on non-core income, and the sharp swing into a Q2 loss is a red flag for shareholders. The Rs 630 lakh preferential warrant issue has boosted share capital but diluted other equity significantly. Investors should view the headline H1 profit with caution given the deteriorating quarterly trend and lack of a visible core business engine.